Hypoxia-induced PIM kinase and laminin-activated integrin &#945;6 mediate resistance to PI3K inhibitors in bone-metastatic CRPC.

Hypoxia-induced PIM kinase and laminin-activated integrin α6 mediate resistance to PI3K inhibitors in bone-metastatic CRPC.

Toth, Rachel K; Tran, Jack D; Muldong, Michelle T; Nollet, Eric A; Schulz, Veronique V; Jensen, Corbin C; Hazlehurst, Lori A; Corey, Eva; Durden, Donald; Jamieson, Christina; Miranti, Cindy K; Warfel, Noel A.

Afiliación

Toth RK; Department of Cellular and Molecular Medicine, Prostate Cancer Group, University of Arizona Cancer Center Tucson, AZ, USA.
Tran JD; Department of Cellular and Molecular Medicine, Prostate Cancer Group, University of Arizona Cancer Center Tucson, AZ, USA.
Muldong MT; Department of Urology, Moores Cancer Center, University of California San Diego La Jolla, CA, USA.
Nollet EA; Van Andel Research Institute, Cancer Biology Program Grand Rapids, MI, USA.
Schulz VV; Van Andel Research Institute, Cancer Biology Program Grand Rapids, MI, USA.
Jensen CC; Department of Cellular and Molecular Medicine, Prostate Cancer Group, University of Arizona Cancer Center Tucson, AZ, USA.
Hazlehurst LA; Department of Pharmaceutical Sciences, West Virginia University Cancer Institute Morgantown, WV, USA.
Corey E; Department of Urology, University of Washington Seattle, WA, USA.
Durden D; Department of Pediatrics, Moores Cancer Center, University of California San Diego CA, USA.
Jamieson C; Department of Urology, Moores Cancer Center, University of California San Diego La Jolla, CA, USA.
Miranti CK; Department of Cellular and Molecular Medicine, Prostate Cancer Group, University of Arizona Cancer Center Tucson, AZ, USA.
Warfel NA; Van Andel Research Institute, Cancer Biology Program Grand Rapids, MI, USA.